Drug recall · June 1, 2022
RE-1 Papaverine 30 mg/mL Phentolamine 3 mg/mL Alprostadil 200 mcg/mL recall
Why: Lack of assurance of sterility.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
RE-1 Papaverine 30 mg/mL Phentolamine 3 mg/mL Alprostadil 200 mcg/mL, packaged as a) 2.5 mL Multi Dose vial, NDC 73198-0015-03; b) 10 mL Multi Dose vial, NDC 73198-0015-10; Rx Only, Olympia Pharmaceuticals, 6700 Conroy Rd., Ste. 155 Orlando, FL 32835
- Lots / codes
Lots: B24E09-22 BUD: 02/09/2023; B24F09-22 BUD: 02/09/2023
- Quantity
- 482 vials
- Company
- Olympia Compounding Pharmacy dba Olympia Pharmacy, Orlando, FL
- Distribution
- Distributed Nationwide in th USA, Puerto Rico and US Virgin Islands
- Initiated
- May 9, 2022 · Voluntary: Firm initiated
- Classified
- May 25, 2022
- Reported
- June 1, 2022
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Papaverine
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.